Clinical Trials Directory

Trials / Unknown

UnknownNCT00907270

Supplementation With Vitamin D Improves Leptin Resistance

Effect of Vitamin D Supplementation on Leptin Resistance, Hunger, Body Weight and Resting Energy Expenditure in Obese Women.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Mexican National Institute of Public Health · Other Government
Sex
Female
Age
45 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Participants will be randomly assigned in one of two groups. Group A: oral supplementation with 4,000 IU of vitamin D (cholecalciferol). Group B: oral supplementation with 400 IU of vitamin D (cholecalciferol). Both treatments will be consumed daily for 6 months. Outcomes will be evaluated at baseline, three and six months. Variables related to leptin resistance will be evaluated. The main hypothesis is that vitamin D will diminish leptin resistance in overweight and obese women. If the hypothesis is confirmed, women will show a reduction in the Resting energy expenditure: serum Leptin ratio (REE: Leptin ratio), as well as a reduction of hunger, body weight, body and abdominal fat and an increase in resting energy expenditure.

Detailed description

Study subjects will get dietary advice and physical activity counseling. At the end of the study, participants with suboptimal vitamin D levels (\<80 nmol/L 25-OH-D) will receive treatment to normalize their vitamin D status. Variables related to leptin resistance like resting metabolic expenditure, hunger, body weight and human body fat will be assessed. Outcomes will include, glucose, insulin, C-reactive protein, inflammatory interleukins (IL-6 \& TNF-α) and non-inflammatory interleukins (IL-10 \& TGF-β-1).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTCholecalciferolCholecalciferol: 4,000 IU/day and 400 IU/day

Timeline

Start date
2009-09-01
Primary completion
2010-05-01
Completion
2010-05-01
First posted
2009-05-22
Last updated
2009-05-22

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT00907270. Inclusion in this directory is not an endorsement.